An Innovation for Sepsis Screening
TCS Biosciences Ltd is pleased to announce our partnership with R&D Antibodies. R&D Antibodies has delivered high quality research antibodies and immunoassays to the life sciences and research markets since 1984.
The PliNOSa® K-1600 Assay Kit is a novel in vitro diagnostic immunoassay for the early identification of sepsis.
The PliNOSa® test detects inducible Nitric Oxide Synthase (iNOS) on microvesicles in plasma, an innovation in sepsis disease pathology.
The PliNOSa® test can help physicians make better and more informed choices for improved patient management.
iNOS has specifically been implicated in sepsis, severe sepsis and septic shock. The PliNOSa® K-1600 assay kit provides accurate measurement of circulating iNOS concentrations in plasma samples via a chemiluminescent sandwich EIA. Each kit is for 96 tests.
- Detects circulating iNOS in plasma.
- Novel biomarker directly involved in sepsis pathology.
- The assay is CE marked.
- Standards and controls are provided.
- Can identify patients at risk as early as 48 hours before clinical symptoms appear.
- Easy to use ELISA test with 8-well strips (x12) for efficiency.
- Compatible with most EIA washers.
The kit includes:
- 12 x 8 well strips with immobilized anti-iNOS capture monoclonal antibody
- HRP-labelled anti-iNOS detection monoclonal antibody
- Wash buffer
- Assay buffer
- Standards and controls
|Table 1 - Organ Dysfunction Associated with Sepsis in Severely Injured Trauma Patients
|N = 187
|Heart, Lung or Kidney Dysfunction
|Sensitivity = 88%
|PPV = 96%
|Specificity = 92%
|NPV = 80%
The Sepsis Pathology via Microvesicles
Until now, sepsis has been an intractable disease that has baffled medical researchers for centuries.
Biochemical markers such as procalcitonin (PCT), IL-6, lactate and CRP have lacked the necessary specificity and sensitivity. These assays often fail to help physicians and clinicians to identify at-risk patients who are progressing down the sepsis pathway.
The PliNOSa® test helps physicians assess a patient's risk of developing sepsis as much as 48 hours before recognisable symptoms appear.
Contact us for more information